Pyruvate Kinase Deficiency Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 26, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Pyruvate Kinase Deficiency. It connects disease background, epidemiology, target mechanism, competition, transactions, unmet need and market attractiveness.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Executive assessment

Pyruvate Kinase Deficiency receives a directional score of 67/100, combining unmet need (81/100), competitive intensity (66/100) and market attractiveness (74/100). It is a prioritization framework, not a revenue forecast or medical recommendation.

Disease background and strategic definition

An inherited metabolic disorder characterized by the deficiency of the erythrocyte enzyme pyruvate kinase. It results in the development of hemolytic anemia.

The reproducible record is Patsnap disease ID 84ac6db684fe4bf49a3931a3dfdcf9bd and MeSH identifier C564858. Stable identifiers prevent historical names, gene-defined subtypes and overlapping syndromic labels from producing inconsistent landscapes.

A target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, setting, safety and endpoint. An overly broad population can inflate market size while weakening biological signal and recruitment. The first population should be biologically coherent and operationally feasible.

Map the pathway from symptom recognition through specialist referral, testing, treatment and monitoring. Diagnostic delay, center concentration and testing access can constrain trials and commercialization as much as drug performance.

Epidemiology and disease burden

Epidemiology evidence 1: USRDS 2022 Annual Data Report - CKD Among Children and Adolescents

We used these data sources to estimate the prevalence of CKD among children in the U.S., to describe demographic characteristics, comorbid conditions, and type of kidney disorders, as well as to examine rates of hospitalization and cost of care for children based on CAKUT and CKD status. Specifically, we utilized a point prevalent cohort of children in Optum's de-identified Clinformatics Data Mart Database (referred to as the “Commercial cohort”) and Medicaid (“Medicaid cohort”) databases on December 31, 2020 who were aged 0-17 years, resided in the 50 US states or District of Columbia, had health insurance coverage for the whole calendar year, did not have ESRD, and were alive on December 31, 2020. When describing types of kidney disorders, rates of hospitalization, and cost of care in children with commercial insurance coverage, because of the small sample size for children with CKD (with or without CAKUT), we combined three yearly cohorts of 2018, 2019, and 2020. ® It is important to note that sample sizes used to estimate the prevalence of low eGFR (eGFR <60 mL/min/1.73 m ) using the various formulas were low. Overall, only 59 children with low eGFR were included in estimations based on the Bedside Schwartz equation, and 29 using the U25 equation. Fewer than 11 children with low eGFR were used to estimate the prevalence of low eGFR in female and Hispanic children by the Bedside Schwartz equation, and in male, Black, or Hispanic children by the U25 equation, meaning that the results by sex and race/ethnicity of Table 5.1 should be interpreted with caution. 2 For a more c

Review source

Epidemiology evidence 2: Heart Disease and Stroke Statistics—2025 Update 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

• The overall prevalence of CKD (incorporating eGFR <60 mL·min−1·1.73 m−2 or ACR ≥30 mg/g) was highest among NH Black adults (18.8%) followed by NH White adults (12.1%) and Hispanic adults (12.0%). The prevalence of CKD decreased com- pared with the previous NHANES cycle (2013– 2016) for NH White adults and Hispanic adults but increased in NH Black adults.1 • In the Framingham Offspring Study, the prevalence of mildly reduced eGFR (60–89 mL·min−1·1.73 m−2) was reported in 62% of participants, higher than reported in the NHANES data, possibly related to the higher age of the cohort.10 • In 2021, the age-, race-, and sex-adjusted preva- lence of ESKD in the United States was 2219 per million people, a decrease of 3.5% from its peak in 2019.1 The overall prevalence count increased slightly, from 807 920 in 2020 to 808 536 in 2021. • ESKD prevalence varied by race and ethnicity (Chart 12-2). In 2021, ESKD prevalence was high- est in Black adults, followed by Native American adults, Hispanic adults, Asian adults, and White adults. ESKD prevalence also was higher among Hispanic people than among NH people. • Among those with prevalent ESKD, in 2021 com- pared with 2020, the use of in-center hemodialysis remained the most common modality but contin- ued to decrease from 59.8% to 58.3% (Chart 12-3). All other modalities increased: transplanta- tion from 30.6% to 31.8%, peritoneal dialysis from 8.1% to 8.3%, and home hemodialysis from 1.5% to 1.6%.1 Incidence (See Chart 12-4)

Review source

Epidemiology evidence 3: Heart Disease and Stroke Statistics—2023 Update Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association

• Analysis of 171 probands with CPVT who were <19 years of age and 65 adult relatives described clinical presentations and prevalence of geno- types.147 The presenting symptom was cardiac arrest for 28% of cases and syncope/seizure in 58%. Genetic testing of 194 individuals identified variants in RYR2 (60%), CASQ2 (5%), and >1 gene in 17 cases (9%). For 23 cases (12%), no genetic variant was identified. Complications • In a cohort of 34 patients with CPVT, 20.6% developed fatal cardiac events during 7.4 years of follow-up.148 • Incidence of SCA in children with ≥2 CPVT gene variants was 11 of 15 (73%).149 VT or exertional syncope occurred in 3 of the children (20%), and only 1 (7%) was asymptomatic. Arrhythmogenic RV Dysplasia/ARVC • Arrhythmogenic RV dysplasia or ARVC is a form of genetically inherited structural HD that pres- ents with fibrofatty replacement of the myocardium, which increases risk for palpitations, syncope, and sudden death attributable to VT.150 • Twelve ARVC loci have been described (ARVC1–ARVC12).151 • Clinical Genomics Resource reappraisal of 26 can- didate ARVC genes found 6 to have strong defini- tive evidence and 2 to have moderate evidence supporting their role in ARVC.152 • Although the original descriptions localized the dis- ease to the RV, more recent work has demonstrated that LV involvement may occur early in the course of the disease.153 Complications • In a cohort of 301 patients with ARVC from a single center in Italy, probability of a first life-threatening arrhythmic event was 14% at 5 years, 23% at 10 years, and 30% at 15 years.154 • I

Review source

Convert population evidence into a funnel: total affected → diagnosed → clinically eligible → treated → realistically accessible. Incidence, point prevalence and lifetime prevalence are not interchangeable. Do not pool incompatible age bands, case definitions or health systems.

For Pyruvate Kinase Deficiency, quantify diagnostic yield, severity distribution, center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges with a source and access date for every parameter. Market models should show which assumptions drive recruitment and adoption.

A small, well-defined population concentrated in expert centers may be more actionable than a larger population with poor diagnosis. Epidemiology therefore must connect to real patient identification, clinical eligibility and access.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: progression, incomplete control, toxicity, weak durability, burdensome delivery, diagnostic delay or absent options for a subgroup. Disease severity alone does not demonstrate that a program can deliver measurable benefit.

A strong Pyruvate Kinase Deficiency thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit is measurable within a feasible period and whether natural-history variability can be controlled.

Proceed through gates: confirm phenotype and natural history, demonstrate engagement, observe pharmacodynamic response, show interpretable clinical signal and only then scale. Pre-agreed stop criteria protect capital and make negative studies informative.

Target mechanism anchor: C5

Precursor of the C5a anaphylatoxin and complement C5b components of the complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:6554279). Activated downstream of classical, alternative, lectin and GZMK complement pathways (PubMed:12878586, PubMed:18204047, PubMed:30643019, PubMed:39914456, PubMed:39814882, PubMed:6554279). Component of the membrane attack complex (MAC), a multiprotein complex activated by the complement cascade, which inserts into a target cell membrane and forms a pore, leading to target cell membrane rupture and cell lysis (PubMed:26841837, PubMed:27052168, PubMed:30552328, PubMed:30643019). Complement C5b is generated following cleavage by C5 convertase and initiates formation of the MAC complex: C5b binds sequentially C6, C7, C8 and multiple copies of the pore-forming subunit C9 (PubMed:30552328, PubMed:30643019). During MAC complex assembly, the C5b6 subcomplex, composed of complement C5b and C6, associates with the outer leaflet of target cell membrane, reducing the energy for membrane bending (PubMed:30552328, PubMed:32569291). Mediator of local inflammatory process released following cleavage by C5 convertase (PubMed:8182049, PubMed:9553099). Acts by binding to its receptor (C5AR1 or C5AR2), activating G protein-coupled receptor signaling and inducing a variety of responses including intracellular calcium release, contraction of smooth muscle, increased vascular permeability, and histamine release from mast cells and basophilic leukocytes (PubMed:36806352, PubMed:37852260, PubMed:37169960, PubMed:8182049, PubMed:9553099). C5a is also a potent chemokine which stimulates the locomotion of polymorphonuclear leukocytes and directs their migration toward sites of inflammation (PubMed:342601, PubMed:37852260, PubMed:37169960, PubMed:5765461, PubMed:8182049, PubMed:9553099).

The mechanism anchor is C5, a testable pathway hypothesis rather than a claim that every patient is target-dependent. Establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and therapeutic window.

Use orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit safety testing. Human evidence should carry more weight than model-only observations. Related failures should be analyzed for exposure, population and endpoint lessons.

A go decision requires a complete chain from relevant biology to achievable modulation, measurable pharmacodynamics and a plausible bridge to clinical benefit. Missing links require targeted experiments, not stronger narrative.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Clinical development and competition

The focused search returned 22 registered studies.

• NCT07612345 — High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study (G6PDA PKD); Not yet recruiting; Phase 1; sponsor University of Utah; enrollment 3.
• NCT07186283 — Pharmacokinetic Study of a Novel Cannabidiol (CBD) Formulation in Healthy Volunteers; Completed; Phase 1; sponsor NW Pharmatech Ltd.; enrollment 14.
• NCT06422351 — Clinical Trial to Evaluate the Efficacy of Gene Therapy for Pyruvate Kinase Deficiency; Suspended; Phase 2; sponsor Rocket Pharmaceuticals, Inc.; enrollment 10.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies for one asset can inflate activity. Normalize records by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact subtype.

Compare against the likely future standard at launch. Whitespace may come from earlier treatment, genotype selection, durability, lower monitoring, safer chronic use or simpler delivery. Differentiation should be visible in protocol design and prospective analyses.

Recruitment risk requires site-density, testing, travel, competing-protocol and screen-failure assumptions. Natural-history evidence can reduce uncertainty but cannot substitute for controlled efficacy evidence when outcomes are variable.

Transactions and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering or broader asset-level indexing; add target and asset searches before valuation.

Separate upfront payments, milestones, royalties, options, bundled assets, platform rights and geographic scope. A defensible comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires disease segmentation, target-validation chain, competition map, clinical plan, intellectual property, manufacturability evidence and a transparent risk-adjusted model. Outreach is strongest around a catalyst that retires material risk.

Low direct deal activity may represent whitespace, but can also signal difficult science or economics. Use broader therapeutic-area transactions only when relevance is explicit; rare-disease deals are not automatically interchangeable.

Market attractiveness and access

Attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, setting, payer controls, alternatives, monitoring and reimbursement. Patient count is only one driver. Reliable identification and meaningful benefit can support a small population; fragmented diagnosis can undermine a larger one.

Build scenarios for diagnosed prevalence, eligible share, timing, competition, net price, persistence and penetration. Keep assumptions traceable and refresh them when new epidemiology, trial or transaction evidence appears.

Begin payer research before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Quality of life, caregiver burden, hospital use and diagnostic costs may be essential to the value case.

Risks, decision gates and recommendation

• Confirm a consistently diagnosed and recruitable population.
• Demonstrate C5 relevance in the selected phenotype.
• Connect engagement to a biomarker and meaningful endpoint.
• Refresh competition before every investment gate.
• Validate sites, testing, access, pricing and adoption.
• Treat zero-result searches as prompts for broader queries, not proof of absence.

Pyruvate Kinase Deficiency merits continued milestone-based evaluation if a coherent subgroup can be identified, target modulation can be measured and benefit remains differentiated against future care. The current evidence supports targeted diligence rather than unconditional investment.

The business-development objective is a partner-ready thesis covering patient segment, mechanism, whitespace, development path and value-inflection milestones. Evidence gaps should remain visible rather than hidden in a composite score.

Methodology and source note

This report was assembled on August 26, 2026 using Patsnap MCP tools: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and can change as databases update.

Weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease profile, epidemiology coverage, registered trials, development-drug counts and direct transactions. Rerun with synonyms, roll-ups, targets and assets before commitment.

Build evidence-backed indication strategy with Patsnap MCP

Connect disease, target, clinical-trial and transaction intelligence through the Patsnap Life Sciences MCP marketplace.

Conclusion

The central question for Pyruvate Kinase Deficiency is whether a biologically grounded therapy can deliver material benefit in an identifiable population and remain differentiated through launch. This evidence provides a starting map; the explicit gaps define the next diligence plan.